FDA approves Exelixis’ cancer drug Cabometyx
January 25, 2021Sales and Marketing Cancer, Exelixis
The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in …
New study challenges link between stress and migraines
January 25, 2021Sales and Marketing Curelator, migraine
Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks. …
Genentech announces positive top-line results for “wet” age-related macular degeneration antibody
January 25, 2021Sales and Marketing Genentech
Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational …
Merck KGaA’s cancer drug Bavencio gets EU approval
January 25, 2021Sales and Marketing Merck KGaA
The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally …
Pharmafile.com’s top 10 news stories of the week
January 22, 2021Medical Communications
A number of Pharmafile.com’s most popular stories this week are surprisingly unrelated to COVID; researchers in Scotland have made a …
NICE rejects multiple sclerosis drug Zeposia
January 22, 2021Medical Communications NICE
NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …
Servier and MiNA partner to develop neurological disorder treatments
January 22, 2021Medical Communications MiNA, Servier
Independent pharmaceutical group Servier and RNA activation-focused MiNA Therapeutics have entered a research partnership to identify and develop small activating …
Lilly’s antibody could reduce COVID-19 risk by 80%, trial shows
January 22, 2021Medical Communications COVID-19, Eli Lilly
Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of long-term care …
ViiV’s long-acting HIV drug Cabenuva gets FDA approval
January 22, 2021Medical Communications HIV, ViiV Healthcare
The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …
Xellia Pharmaceuticals becomes member of Medicines for Europe
January 21, 2021Europe, xellia
Xellia Pharmaceuticals, a manufacturer of specialty anti-infective treatments, has become a member of Medicines for Europe. Medicines for Europe represents …
GSK and Eligo enter acne research partnership
January 21, 2021GlaxoSmithKilne, acne
Eligo Bioscience has entered into a research and option agreement with GlaxoSmithKline (GSK) aimed at advancing Eligobiotics for the treatment …
Researchers and pharma companies partner to investigate new schizophrenia treatment
January 21, 2021Biogen, Boehringer Ingelheim
The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …
Thousands of Israelis test positive for COVID-19 after receiving Pfizer jab
January 21, 2021COVID-19, Pfizer, israel
Thousands of people in Israel have tested positive for coronavirus after receiving the Pfizer vaccine, including some who had been …
NICE recommends rheumatoid arthritis drug Jyseleca for NHS use
January 21, 2021Gilead, NICE
NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …
Raremark appoints Nicki Grundy as CFO
January 20, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Raremark, a global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer. As a key …
Pharmafile.com’s weekly COVID-19 news round-up
January 20, 2021Research and Development
The past week has seen promising developments in the race to find treatments for COVID-19; Jubilant and The Wistar Institute …
Scientists in Scotland make breakthrough MND discovery
January 20, 2021Research and Development motor neurone disease
Researchers in Scotland have made a discovery that could reverse the damage caused by motor neurone disease (MND). University of …
NICE approves lipid disorder drug Myalepta for NHS use
January 20, 2021Research and Development Amryt Pharma, NICE
NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …
EU approves breast cancer drug Enhertu
January 20, 2021Research and Development AstraZeneca, Daiichi Sankyo
The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …
Pfizer-BioNTech COVID-19 vaccine likely to protect against UK variant, study says
January 20, 2021Research and Development COVID-19, Pfizer
The Pfizer-BioNTech COVID-19 vaccine is likely to protect against the coronavirus variant found in Britain, the latest research says. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
